ANS-6637 is in Clinical Development to Treat Substance Use Disorders
Amygdala Neurosciences is developing ANS-6637 a new chemical entity with a novel MOA for treating substance use disorder and behavior based addictions. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving and relapse.
In pre-clinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anxiolytic properties in models of stress. ANS-6637 has completed extensive Phase 1 studies and is ready for Phase 2 efficacy studies.
In 2019, NIH will be funding and conducting 2 Phase 2 proof-of-concept studies with ANS-6637: one for Alcohol Use Disorder and a second for Opioid Use Disorder. Amygdala is also making plans for additional Phase 2 proof-of-concept studies for Opioid Use Disorder and Smoking Cessation.
AMYGDALA PRESS RELEASE: Sept 12, 2018
In addition to Lou Lange, Ivan Diamond, and Peter Strumph, the BOD includes:
Improved Public Health from Reduced Substance Abuse
Develop and Commercialize Safe, Effective, and Widely Used Pharmacotherapies to Treat and Prevent Addiction
Ivan Diamond, MD, PhD, Chief Scientific Officer and Founder
Lou Lange, MD, PhD, Executive Chairman and Founder
Adrienne MacMillan, Chief Financial Officer and Founder
AMYGDALA PRESS RELEASE: Feb 16, 2017
Peter Strumph, President and Chief Executive Officer and Founder
Brent Blackburn, PhD, Chief Development Officer and Founder
NIH/IHV PRESS RELEASE: Sept 19, 2018
The Board of Directors
William Lee, PhD, Executive Vice President Research, Gilead Sciences
Mack Mitchell, MD, VP Medical Affairs & EVP Health System UTSW; CMO Southwestern HRPN
Howard Jaffe, MD, President and COB of the Gilead Foundation. Former CMO Gilead Sciences
The Amygdala founders have deep and varied expertise in drug development and the addiction space. In addition to our individual experiences, we are all former members of the executive management team that built CV Therapeutics into a FIPCO and developed two first-in-class NCEs approved in the US and EU and achieved guideline status in both territories with current global revenues over $1.6B.
NIH PRESS RELEASE: March 21, 2019